Trade Summary

3 months ago, Lettmann Jason, serving as CEO at Alx Oncology Holdings Inc (ALXO), purchased 92,233 shares at $1.08 per share, for a total transaction value of $99,352.00. Following this transaction, Lettmann Jason now holds 305,121 shares of ALXO.

This purchase represents a 43.00% increase in Lettmann Jason's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, September 16, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, September 18, 2025, 2 days after the trade was made.

Alx Oncology Holdings Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.